Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients.

Trial Profile

Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Bial
  • Most Recent Events

    • 27 Apr 2018 Results of analysis investigating MCID in seizure frequency using patient data pooled from NCT01422720, NCT00957047 and NCT00988429 trials presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Jul 2017 Results of a post-hoc pooled analysis of safety data from NCT00957684, NCT00957047, NCT00957372 NCT00988429, NCT02281422, NCT02281526 and NCT01422720 studies published in the Drug Safety
    • 17 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top